Exscientia Accelerates COVID-19 Drug Discovery Using AI
Funding from the COVID-19 Therapeutics Accelerator to advance Exscientia’s novel class of AI-designed coronavirus SARS-CoV-2 Mpro inhibitors to development candidates Exscientia has received a grant from...